Compare Davita Inc (DVA) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Davita Inc trades at $178.01 (market cap $11.29B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.15 (market cap $560.32M). The key difference: Davita Inc is far larger — about 20.1× Direxion Daily FTSE China Bull 3x Shares's market cap, and Davita Inc is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| DVA | YINN | |
|---|---|---|
Market Cap | $11.29B | $560.32M |
Volume | 582,204 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $240.96 | $52.69 |
52-Week Low | $103.87 | $21.45 |
Typical Hold Time | 113 Days | 25 Days |
Enterprise Value | $24.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
YINN is trading at $23.56, down 2.97% with bearish technical indicators showing 18 sell signals versus 1 buy. The stock faces resistance at $24 with support at $23. Recent corporate actions include a $0.56 dividend scheduled for September 2026. Technical analysis indicates strong bearish momentum with moving averages unanimously negative.
The outlook remains challenging with bearish technical positioning and limited fundamental data availability. Key risks include market volatility and sector-specific headwinds. Investment opportunities may emerge if the stock stabilizes above support levels, but current momentum suggests continued downward pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
